Table 1.
Patient demographics and baseline characteristics for subjects receiving DPX-Survivac with or without cyclophosphamide*
| Cohort A | Cohort B | Cohort C | Total | |
|---|---|---|---|---|
| Number of Subjects | 7** | 6 | 6 | 19 |
| Median Age (Range) | 58 (41–72) | 54 (35–65) | 60 (47–69) | 59 (35–72) |
| Cancer Type: Ovarian | 7 | 6 | 6 | 19 |
| Fallopian Tube | 0 | 0 | 0 | 0 |
| Peritoneal | 0 | 0 | 0 | 0 |
| Stage at Diagnosis: I | 0 | 0 | 1 | 1 |
| II | 0 | 1 | 1 | 2 |
| III | 6 | 5 | 3 | 14 |
| IV | 1 | 0 | 1 | 2 |
| ECOG Status: 0 | 5 | 6 | 6 | 17 |
| 1 | 2 | 0 | 0 | 2 |
| 1st Line Patients | 5 | 4 | 2 | 11 |
| Recurrent Patients | 2 | 2 | 4 | 8 |
| Route of Chemotherapy: IV | 4 | 3 | 4 | 11 |
| IP | 3 | 3 | 2 | 8 |
| Neoadjuvant Treatment | 1 | 2 | 1 | 4 |
| Avastin | 0 | 1 | 2 | 3 |
| Measurable Disease | 2 | 2 | 2 | 6 |
| Median Time from Diagnosis to Study Day –8 (Range) | 13 months (5–53) | 15 months (6–81) | 39 months (28–46) | 28 months (5–81) |
| Elevated CA-125 (>30 U) | 0 | 2 | 0 | 2 |
*
all subjects identified race as “white”; **only 6 subject received a full course